Citadel Advisors
ROIV icon

Citadel Advisors’s Roivant Sciences ROIV Stock Holding History

Citadel Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.77M Sell
100,100
-262,700
-72% -$6.75M ﹤0.01% 5424
2025
Q4 		$7.87M Buy
362,800
+110,100
+44% +$2.17M ﹤0.01% 3584
2025
Q3 		$3.82M Buy
252,700
+114,000
+82% +$1.41M ﹤0.01% 4857
2025
Q2 		$1.56M Buy
138,700
+41,200
+42% +$447K ﹤0.01% 6179
2025
Q1 		$984K Buy
97,500
+58,800
+152% +$636K ﹤0.01% 6992
2024
Q4 		$458K Sell
38,700
-13,100
-25% -$155K ﹤0.01% 8756
2024
Q3 		$598K Sell
51,800
-17,600
-25% -$200K ﹤0.01% 7884
2024
Q2 		$734K Sell
69,400
-27,800
-29% -$305K ﹤0.01% 7266
2024
Q1 		$1.02M Buy
97,200
+49,800
+105% +$537K ﹤0.01% 6864
2023
Q4 		$532K Buy
47,400
+17,900
+61% +$174K ﹤0.01% 7958
2023
Q3 		$345K Sell
29,500
-21,100
-42% -$239K ﹤0.01% 8879
2023
Q2 		$510K Buy
50,600
+12,800
+34% +$114K ﹤0.01% 7900
2023
Q1 		$279K Sell
37,800
-35,500
-48% -$292K ﹤0.01% 9518
2022
Q4 		$586K Buy
73,300
+30,100
+70% +$167K ﹤0.01% 7912
2022
Q3 		$139K Buy
43,200
+30,300
+235% +$117K ﹤0.01% 10794
2022
Q2 		$53K Buy
+12,900
New +$51.2K ﹤0.01% 11898

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's ROIV Position: Q1 2026 in Review

Citadel Advisors increased its Roivant Sciences (ROIV) stake by 10% in Q1 2026, buying an estimated $5.91M and bringing the position to 2,515,998 shares worth $69.7M. The position accounts for 0.01% of the portfolio, ranked #1089.

Citadel Advisors first reported a position in ROIV in Q2 2022 and has held it in 16 quarters since. 440 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • Citadel Advisors held 2,515,998 shares of Roivant Sciences worth $69.7M as of Q1 2026.
  • Citadel Advisors bought 229,997 Roivant Sciences shares in Q1 2026, an estimated $5.91M.
  • Roivant Sciences made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1089 holding.
  • Citadel Advisors first reported a position in Roivant Sciences in Q2 2022 and has held it in 16 quarters since.
  • 440 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.